Critical Comparison: Vericel (VCEL) vs. Trius Therapeutics (TSRX)

Trius Therapeutics (NASDAQ: TSRX) and Vericel (NASDAQ:VCEL) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings and analyst recommendations.

Profitability

This table compares Trius Therapeutics and Vericel’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Trius Therapeutics N/A N/A N/A
Vericel -45.11% -265.45% -52.01%

Institutional and Insider Ownership

33.1% of Vericel shares are held by institutional investors. 3.3% of Vericel shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings for Trius Therapeutics and Vericel, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trius Therapeutics 0 0 0 0 N/A
Vericel 0 0 3 0 3.00

Vericel has a consensus target price of $7.67, indicating a potential upside of 7.98%.

Earnings & Valuation

This table compares Trius Therapeutics and Vericel’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Trius Therapeutics N/A N/A N/A ($1.60) N/A
Vericel $54.38 million 4.56 -$19.56 million ($0.88) -8.07

Trius Therapeutics has higher earnings, but lower revenue than Vericel. Vericel is trading at a lower price-to-earnings ratio than Trius Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Vericel beats Trius Therapeutics on 5 of the 8 factors compared between the two stocks.

About Trius Therapeutics

Trius Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of antibiotics for life threatening infections. The Company is developing torezolid phosphate, an intraveneous (IV) and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections (ABSSSI), and subsequently for other indications. In addition, the Company is developing antibiotics for gram-negative infections using its discovery platform under two contracts: one funded by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH) and the other funded by the Defense Threat Reduction Agency (DTRA), a part of the Department of Defense. In September 2013, Cubist Pharmaceuticals Inc announced that it has completed the acquisition of Trius Therapeutics Inc.

About Vericel

Vericel Corporation, formerly Aastrom Biosciences, Inc., is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment. Its autologous cell therapy products include Carticel (autologous cultured chondrocytes), which is an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), which is a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns. The Company is developing MACI, which is a third-generation autologous chondrocyte implant and ixmyelocel-T, which is a patient-specific multicellular therapy.

Receive News & Ratings for Trius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply